Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Omaveloxolone
Cat. No.:
0225LY-1428
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Omaveloxolone is a synthetic triterpenoid currently in clinical development that works by inhibiting NF-κB signaling and activating the protective Nrf2 transcription factor.
Synonym:
RTA-408; 1474034-05-3; Omaveloxolone; N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide; G69Z98951Q; Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-; N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide; N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2H-picen-4a-yl)-2-2-difluoropropionamide; Skyclarys (TN); N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-Cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydropicen-4a(2H)-yl)-2,2-difluoropropanamide; N-(2-Cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide
CAS No.:
1474034-05-3
Compound CID:
71811910
Formula:
C33H44F2N2O3
Formula Weight:
554.71
Specification
Relative Density:
1.19 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Omaveloxolone can be used in neurobiology research to investigate the activation of the Nrf2 pathway in treating degenerative diseases.
Library Information
Target:
STING; Nrf2; Keap1
Receptor:
STING; Nrf2; Keap1
Pathways:
Immunology/Inflammation; Apoptosis
Plate Number:
AOCL-19
Plate Location:
c11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
240 mg/mL; 432.66 mM
Water Max Solubility:
<1 mg/mL (insoluble)
Ethanol Max Solubility:
16 mg/mL; 28.84 mM
ALogP:
5.339
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
2
